On Oct. 12, 2021, Inovio Pharmaceuticals announced online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800.

The paper reported that among the full Phase 1 cohort of 120 participants ﾖ of which 82.5%, or 99 participants, received a booster (or third) dose ﾖ INO-4800 produced robust immune responses and was well-tolerated as both a two-dose series and as a homologous booster dose in all adults, including participants 65 years of age and older.